Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.

Sheriza N BakshJodi B SegalMara McAdams-DeMarcoRita R KalyaniG Caleb AlexanderStephan Ehrhardt

Published in: PloS one (2020)

Our findings show that for this cohort of low-risk patients newly treated for type 2 diabetes, DPP-4i exhibited 13% lower risk for MACE compared to sulfonylureas and similar risk for MACE compared to metformin, suggesting DPP-4i is a low cardiovascular risk option for low-risk patients initiating antihyperglycemic treatment.

Keyphrases

cardiovascular events
end stage renal disease
type diabetes
newly diagnosed
ejection fraction
chronic kidney disease
cardiovascular disease
metabolic syndrome
adipose tissue
patient reported
smoking cessation